ABSTRACT
An efficient and safe delivery system for the transfection of CRISPR plasmid (p/CRISPR) into target cells can open new avenues for the treatment of various diseases. Herein, we design a novel nonvehicle by integrating an arginine-disulfide linker with low-molecular-weight PEI (PEI1.8k) for the delivery of p/CRISPR. These PEI1.8k-Arg nanoparticles facilitate the plasmid release and improve both membrane permeability and nuclear localization, thereby exhibiting higher transfection efficiency compared to native PEI1.8kin the delivery of nanocomplexes composed of PEI1.8k-Arg and p/CRISPR into conventional cells (HEK 293T). This nanovehicle is also able to transfect p/CRISPR in a wide variety of cells, including hard-to-transfect primary cells (HUVECs), cancer cells (HeLa), and neuronal cells (PC-12) with nearly 5-10 times higher efficiency compared to the polymeric gold standard transfection agent. Furthermore, the PEI1.8k-Arg nanoparticles can edit the GFP gene in the HEK 293T-GFP reporter cell line by delivering all possible forms of CRISPR/Cas9 system (e.g. plasmid encoding Cas9 and sgRNA targeting GFP, and Cas9/sgRNA ribonucleoproteins (RNPs) as well as Cas9 expression plasmid andin vitro-prepared sgRNA) into HEK 293T-GFP cells. The successful delivery of p/CRISPR into local brain tissue is also another remarkable capability of these nanoparticles. In view of all the exceptional benefits of this safe nanocarrier, it is expected to break new ground in the field of gene editing, particularly for therapeutic purposes.
Subject(s)
Arginine/chemistry , CRISPR-Cas Systems/genetics , Nanoparticle Drug Delivery System/chemistry , Nanoparticles/chemistry , Polyelectrolytes/chemistry , Transfection/methods , Animals , Brain/metabolism , Cells, Cultured , Gene Editing , HEK293 Cells , Human Umbilical Vein Endothelial Cells , Humans , PC12 Cells , Plasmids/chemistry , Plasmids/pharmacokinetics , RatsABSTRACT
This study investigates the potential of iron oxide nanoparticles (Fe3O4) and quince seed mucilage as combined genetic carriers to deliver plasmid DNA (pDNA) through the gastrointestinal system. The samples are characterized by x-ray diffraction (XRD), zeta potential, dynamic light scattering, FT-IR spectroscopy, field emission scanning electron microscopy and vibrating sample magnetometry. The stability of pDNA loading on the nanocarriers and their release pattern are evaluated in simulated gastrointestinal environments by electrophoresis. The XRD patterns reveal that the nanocarriers could preserve their structure during various synthesis levels. The saturation magnetization (Ms) of the Fe3O4cores are 56.48 emu g-1without any magnetic hysteresis. Not only does the loaded pDNA contents experience a remarkable stability in the simulated gastric environment, but also, they could be released up to 99% when exposed to an alkaline environment similar to the intestinal fluid of fish. The results indicate that the synthesized nanoparticles could be employed as efficient low-cost pDNA carriers.
Subject(s)
Gene Transfer Techniques , Magnetite Nanoparticles/chemistry , Nanoparticle Drug Delivery System/chemistry , Plant Mucilage/chemistry , Plasmids , DNA/chemistry , DNA/pharmacokinetics , Particle Size , Plasmids/chemistry , Plasmids/pharmacokinetics , Rosaceae/chemistry , Seeds/chemistryABSTRACT
PURPOSE: Nucleic acid-based therapies are a promising therapeutic tool. The major obstacle in their clinical translation is their efficient delivery to the desired tissue. We developed a novel nanosized delivery system composed of conjugates of α-tocopherol, polyethyleneimine, and polyethylene glycol (TPP) to deliver nucleic acids. METHODS: We synthesized a panel of TPP molecules using different molecular weights of PEG and PEI and analyzed with various analytical approaches. The optimized version of TPP (TPP111 - the 1:1:1 molecular ratio) was self-assembled in water to produce nanostructures and then evaluated in diversified in vitro and in vivo studies. RESULTS: Through a panel of synthesized molecules, TPP111 conjugate components self-assembled in water, forming globular shaped nanostructures of ~90 nm, with high nucleic acid entrapment efficiency. The polymer had low cytotoxicity in vitro and protected nucleic acids from nucleases. Using a luciferase-expressing plasmid, TPP111-plasmid nano-complexes were rapidly up-taken by cancer cells in vitro and induced strong transfection, comparable to PEI. Colocalization of the nano-complexes and endosomes/lysosomes suggested an endosome-mediated uptake. Using a subcutaneous tumor model, intravenously injected nano-complexes preferentially accumulated to the tumor area over 24 h. CONCLUSION: These results indicate that we successfully synthesized the TPP111 nanocarrier system, which can deliver nucleic acids in vitro and in vivo and merits further evaluation.
Subject(s)
Nanostructures/administration & dosage , Nucleic Acids/administration & dosage , Polyethylene Glycols/chemistry , Polyethyleneimine/chemistry , alpha-Tocopherol/chemistry , A549 Cells , Animals , Drug Delivery Systems/methods , Endosomes/drug effects , Female , Gene Transfer Techniques , Humans , Luciferases/genetics , Mice, Nude , Molecular Weight , Nanostructures/chemistry , Nanostructures/toxicity , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/pharmacokinetics , Polymers/chemical synthesis , Tissue Distribution , Transfection/methods , Xenograft Model Antitumor AssaysABSTRACT
Vaccines are one of the most powerful technologies supporting public health. The adaptive immune response induced by immunization arises following appropriate activation and differentiation of T and B cells in lymph nodes. Among many parameters impacting the resulting immune response, the presence of antigen and inflammatory cues for an appropriate temporal duration within the lymph nodes, and further within appropriate subcompartments of the lymph nodes- the right timing and location- play a critical role in shaping cellular and humoral immunity. Here we review recent advances in our understanding of how vaccine kinetics and biodistribution impact adaptive immunity, and the underlying immunological mechanisms that govern these responses. We discuss emerging approaches to engineer these properties for future vaccines, with a focus on subunit vaccines.
Subject(s)
Vaccines/immunology , Vaccines/pharmacokinetics , Adjuvants, Immunologic/pharmacology , B-Lymphocytes/immunology , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Humans , Immunity, Humoral/immunology , Inflammation Mediators/metabolism , Liposomes/metabolism , Lymph Nodes/immunology , Nanoparticles/metabolism , Plasmids/pharmacokinetics , RNA, Messenger/pharmacokinetics , T-Lymphocytes/immunology , Tissue DistributionABSTRACT
The objective of the present investigation was to design a targeted polyethylenimine (PEI)-based polyplex by conjugating lactose bearing galactose groups on low molecular weight PEI (LMW PEI) grafted to a high molecular weight PEI (HMW PEI) via a succinic acid linker in order to restore the amine content of the whole conjugate used for ligand conjugation. The PEI conjugate was synthesized and characterized in terms of buffering capacity, particle size, zeta potential, plasmid condensation ability, and protection of DNA against degrading enzymes. Also, the transfection efficiency and cytotoxicity were evaluated in the cell line over-expressing asialoglycoprotein receptors (ASGPRs) and compared with the cells lacking the receptors. The results demonstrated the ability of PEI conjugate in condensation of plasmid DNA and protection against enzyme degradation. The PEI conjugate formed nanoparticles of around 75 nm with higher buffering capacity compared with unmodified PEI. The polyplexes prepared by the modified PEI could increase the level of transgene up to four folds in the cells over-expressing the receptor. The results demonstrated the separation of targeting and delivery domains could be considered as a strategy to restore the amine content of the PEI molecule utilized for targeting ligand conjugation.
Subject(s)
Interleukin-12/genetics , Nanoparticles , Plasmids , Polyethyleneimine/chemistry , Transfection/methods , Asialoglycoprotein Receptor/metabolism , Cell Survival/drug effects , Escherichia coli , Hep G2 Cells , Humans , Interleukin-12/analysis , Interleukin-12/metabolism , Nanoparticles/chemistry , Nanoparticles/metabolism , Nanoparticles/toxicity , Plasmids/chemistry , Plasmids/genetics , Plasmids/pharmacokineticsABSTRACT
Organically modified silica (ORMOSIL) nanoparticles have found many biomedical applications and emerged as biocompatible and efficient carriers of diagnostic and therapeutic agents, such as fluorophores, drugs, and DNA. Herein, we describe two major in vivo studies exemplifying the use of these nanoparticles as carriers of active agents. The first part of this report details a systemic administration and biodistribution of radiolabeled and fluorophore-incorporated ORMOSIL nanoparticles in mice. The second part of this report focuses on the use of ORMOSIL nanoparticles as carriers of plasmid DNA for nonviral gene delivery to the mouse brain. We provide detailed protocols describing preparation and characterization of ORMOSIL nanoparticles, methods used for loading the particles with active agents (e.g., radioimaging agents, plasmid DNA), and in vivo administration of the particles.
Subject(s)
Brain/metabolism , Plasmids/administration & dosage , Siloxanes/chemistry , Animals , Biological Availability , Drug Delivery Systems , Female , Fluorescent Dyes/chemistry , Iodine Radioisotopes/chemistry , Mice , Nanoparticles , Plasmids/genetics , Plasmids/pharmacokinetics , Siloxanes/pharmacokineticsABSTRACT
Tryptophan hydroxylase-type 2 (Tph2) is the first rate-limiting step in the biosynthesis of serotonin (5-HT) in the brain. The ophthalmic administration (Op-Ad) is a non-invasive method that allows delivering genetic vehicles through the eye and reaches the brain. Here, the murine Tph2 gene was cloned in a non-viral vector (pIRES-hrGFP-1a), generating pIRES-hrGFP-1a-Tph2, plus the FLAG-tag. Recombinant Tph2-FLAG was detected and tested in vitro and in vivo, where 25 µg of pIRES-hrGFP-1a-Tph2-FLAG was Op-Ad to mice. The construct was capable of expressing and producing the recombinant Tph2-FLAG in vitro and in vivo. The in vivo assays showed that the construct efficiently crossed the Hemato-Ocular Barrier and the Blood-Brain Barrier, reached brain cells, passed the optical nerves, and transcribed mRNA-Tph2-FLAG in different brain areas. The recombinant Tph2-FLAG was observed in amygdala and brainstem, mainly in raphe dorsal and medial. Relative Tph2 expression of threefold over basal level was recorded three days after Op-Ad. These results demonstrated that pIRES-hrGFP-Tph2-FLAG, administrated through the eyes was capable of reaching the brain, transcribing, and translating Tph2. In conclusion, this study showed the feasibility of delivering therapeutic genes, such as the Tph2, the first enzyme, rate-limiting step in the 5-HT biosynthesis.
Subject(s)
Blood-Brain Barrier/metabolism , Gene Expression , Optic Nerve/metabolism , Plasmids , Recombinant Fusion Proteins , Tryptophan Hydroxylase , Administration, Ophthalmic , Animals , Blood-Brain Barrier/cytology , HEK293 Cells , Humans , Male , Mice , Mice, Inbred BALB C , Optic Nerve/cytology , Plasmids/genetics , Plasmids/pharmacokinetics , Plasmids/pharmacology , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Tryptophan Hydroxylase/biosynthesis , Tryptophan Hydroxylase/geneticsABSTRACT
The optimal conditions for the preparation of superparamagnetic chitosan plasmid (pReceiver-M29-VEGF165/DH5a) gelatin microspheres (SPCPGMs) were determined. Then, the performance of the SPCPGMs during neovascularization was evaluated in vivo. The SPCPGMs were prepared through a cross-linking curing method and then filled into the hollow scaffold of an artificial bone. Neovascularization at the bone defect position was histologically examined in samples collected 2, 4, 6, and 8 weeks after the operation. The cellular magnetofection rate of superparamagnetic chitosan nanoparticles/plasmid (pReceiver-M29-VEGF165/DH5a) complexes reached 1-3% under static magnetic field (SMF). Meanwhile, the optimal conditions for SPCPGM fabrication were 20% Fe3 O4 (w/v), 4 mg of plasmid, 5.3 mg of glutaraldehyde, and 500 rpm of emulsification rotate speed. Under oscillating magnetic fields (OMFs), 4-6 µg of plasmids was released daily for 21 days. Under the combined application of SMF and OMF, evident neovascularization occurred at the bone defect position 6 weeks after the operation. This result is expected to provide a new type of angiogenesis strategy for the research of bone tissue engineering.
Subject(s)
Chitosan , Gelatin , Magnetic Iron Oxide Nanoparticles/chemistry , Microspheres , Neovascularization, Physiologic , Plasmids , Radius/blood supply , Vascular Endothelial Growth Factor A , Animals , Chitosan/chemistry , Chitosan/pharmacokinetics , Chitosan/pharmacology , Gelatin/chemistry , Gelatin/pharmacokinetics , Gelatin/pharmacology , Gene Transfer Techniques , Neovascularization, Physiologic/drug effects , Neovascularization, Physiologic/genetics , Plasmids/chemistry , Plasmids/genetics , Plasmids/pharmacokinetics , Plasmids/pharmacology , Rabbits , Radius/metabolism , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor A/geneticsABSTRACT
The delivery of plasmid DNA (pDNA) using polycations has been investigated for several decades; however, obstacles that limit efficient gene delivery still hinder the clinical application of gene therapy. One of the major limiting factors is controlling pDNA binding affinity with polymers to control the complexation and decomplexation of polyplexes. To address this challenge, polycations of α-poly(L-lysine) (APL) and ε-poly(L-lysine) (EPL) were used to prepare variable complexation/decomplexation polyplexes with binding affinities ranging from too tight to too loose and sizes ranging from small to large. APL-EPL/ATP-pDNA polyplexes were also prepared to compare the effects of endosomolytic ATP on complexation/decomplexation and the sizes of polyplexes. The results showed that smaller and tighter polyplexes delivered more pDNA into the cells and into the nucleus than the larger and looser polyplexes. Larger polyplexes exhibited slower cytosolic transport and consequently less nuclear delivery of pDNA than smaller polyplexes. Tighter polyplexes exhibited poor pDNA release in the nucleus, leading to no improvement in transfection efficiency. Thus, polyplexes should maintain a balance between complexation and decomplexation and should have optimal sizes for effective cellular uptake, cytosolic transport, nuclear import, and gene expression. Understanding the effects of complexation/decomplexation and size is important when designing effective polymer-based electrostatic gene carriers.
Subject(s)
DNA/chemistry , Plasmids/chemistry , Polymers/chemistry , Transfection/methods , Active Transport, Cell Nucleus , Adenosine Triphosphate/chemistry , Adenosine Triphosphate/metabolism , Cell Nucleus/metabolism , Cytoplasm/metabolism , DNA/genetics , DNA/pharmacokinetics , Drug Liberation , HEK293 Cells , Hep G2 Cells , Humans , Particle Size , Plasmids/genetics , Plasmids/pharmacokinetics , Polylysine/chemistry , Static ElectricityABSTRACT
Fluorinated intermediate molecular weight polyethylenimine (FP2ks) with various fluorination degrees was synthesized by conjugation with heptafluorobutyric anhydride and the fluorination effect for gene delivery systems was examined. FP2ks could condense pDNA, forming compact, positively charged, and nano-sized spherical particles. It was thought that their decreased electrostatic interaction with pDNA would be compensated by hydrophobic interaction. The cytotoxicity of FP2ks was increased with the increase of fluorination degree, probably due to the cellular membrane disruption via hydrophobic interaction with FP2ks. The transfection efficiency of highly fluorinated FP2ks was not severely affected in serum condition, assuming their good serum-compatibility. Discrepancy between their higher cellular uptake efficiency and lower transfection efficiency than PEI25k was thought to arise from the formation of compact polyplexes followed by the decreased dissociation of pDNA. It was also suggested that multiple energy-dependent cellular uptake mechanisms and endosome buffering would mediate the transfection of FP2ks.
Subject(s)
Fluorocarbon Polymers , Gene Transfer Techniques , Halogenation , Plasmids , Polyethyleneimine , A549 Cells , Fluorocarbon Polymers/chemical synthesis , Fluorocarbon Polymers/chemistry , Fluorocarbon Polymers/pharmacokinetics , Fluorocarbon Polymers/pharmacology , HeLa Cells , Humans , Molecular Weight , Plasmids/chemistry , Plasmids/pharmacokinetics , Plasmids/pharmacology , Polyethyleneimine/chemical synthesis , Polyethyleneimine/chemistry , Polyethyleneimine/pharmacokinetics , Polyethyleneimine/pharmacologyABSTRACT
Genome editing therapies hold great promise for the cure of monogenic and other diseases; however, the application of nonviral gene delivery methods is limited by both a lack of fundamental knowledge of interactions of the gene-carrier in complex animals and biocompatibility. Herein, we characterize nonviral gene delivery vehicle formulations that are based on diblock polycations containing a hydrophilic and neutral glucose block chain extended with cationic secondary amines of three lengths, poly(methacrylamido glucopyranose- block-2-methylaminoethyl methacrylate) [P(MAG- b-MAEMt)-1, -2, -3]. These polymers were formulated with plasmid DNA to prepare polyelectrolyte complexes (polyplexes). In addition, two controls, P(EG- b-MAEMt) and P(MAEMt), were synthesized, formulated into polyplexes and the ex vivo hemocompatibility, or blood compatibility, and in vivo biodistribution of the formulations were compared to the glycopolymers. While both polymer structure and N/P (amine to phosphate) ratio were important factors affecting hemocompatibility, N/P ratio played a stronger role in determining polyplex biodistribution. P(EG- b-MAEMt) and P(MAEMt) lysed red blood cells at both high and low N/P formulations while P(MAG- b-MAEMt) did not significantly lyse cells at either formulation at short and medium polymer lengths. Conversely, P(MAG- b-MAEMt) did not affect coagulation at N/P = 5, but significantly delayed coagulation at N/P = 15. P(EG- b-MAEMt) and P(MAEMt) did not affect coagulation at either formulation. After polymer and pDNA cargo distribution was observed in vivo, P(EG- b-MAEMt) N/P = 5 and P(MAG- b-MAEMt) N/P = 5 both dissociated and deposited polymer in the liver, while pDNA cargo from P(MAG- b-MAEMt) N/P = 15 was found in the liver, lungs, and spleen. The contrast between P(MAG- b-MAEMt) at N/P = 5 and 15 demonstrates that polyplex stability in the blood can be improved with N/P ratio and potentially aid polyplex biodistribution through simply varying the formulation ratios.
Subject(s)
DNA , Gene Transfer Techniques , Materials Testing , Plasmids , Polyelectrolytes , Animals , DNA/chemistry , DNA/pharmacokinetics , DNA/pharmacology , Humans , Hydrophobic and Hydrophilic Interactions , Methacrylates/chemistry , Methacrylates/pharmacology , Mice , Plasmids/chemistry , Plasmids/pharmacokinetics , Plasmids/pharmacology , Polyelectrolytes/chemistry , Polyelectrolytes/pharmacokinetics , Polyelectrolytes/pharmacology , Tissue DistributionABSTRACT
Efficient gene delivery and expression in the skin can be a promising minimally invasive technique for therapeutic clinical applications for immunotherapy, vaccinations, wound healing, cancer, and peripheral artery disease. One of the challenges for efficient gene electrotransfer (GET) to skin in vivo is confinement of expression to the epithelium. Another challenge involves tissue damage. Optimizing gene expression profiles, while minimizing tissue damage are necessary for therapeutic applications. Previously, we established that heating pretreatment to 43⯰C enhances GET in vitro. We observed a similar trend in vivo, with an IR-pretreatment for skin heating prior to GET. Currently, we tested a range of GET conditions in vivo in guinea pigs with and without preheating the skin to ~43⯰C. IR-laser heating and conduction heating were tested in conjunction with GET. In vivo electrotransfer to the skin by moderately elevating tissue temperature can lead to enhanced gene expression, as well as achieve gene transfer in epidermal, dermal, hypodermal and muscle tissue layers.
Subject(s)
DNA/administration & dosage , Electroporation/instrumentation , Gene Transfer Techniques/instrumentation , Plasmids/administration & dosage , Animals , DNA/genetics , DNA/pharmacokinetics , Female , Gene Expression , Guinea Pigs , Heating , Plasmids/genetics , Plasmids/pharmacokinetics , Skin/metabolismABSTRACT
The development of multifunctional carriers incorporating genetic and photodynamic therapy (PDT) for synergistic antitumor treatment has attracted intensive interests very recently. However, most of the currently reported systems employ passive gene release strategies depending on tumor microenvironment, which are negatively affected by the heterogeneity of cancer cells, thus resulting in limited controllability in therapeutic progress. Herein, a novel photo-responsive hollow silica nanoparticle (HNP)-based gene and photosensitizer (PS) co-delivery nanovehicle is designed for dual-wavelength light-triggered synergistic gene and PDT therapy. The resultant HNP conjugated with PDMAEMA polycation through a 405-nm light-cleavable Cou-linker, namely, HNP-Cou-PD, exhibits excellent gene condensation capacity, good biocompatibility, outstanding PS loading ability, and light-triggered gene release properties. HNP-Cou-PD with Chlorin e6 (Ce6) loaded inside the silica cavity and a plasmid encoding caspase-8 gene (CSP8) attached to the PDMAEMA outside layer (Ce6-HNP-Cou-PD/CSP8) has been proven to possess better antitumor effects under the irradiation of pre-405-nm and post-670-nm light both in vitro and in vivo because of the light-triggered intracellular gene release and reactive oxygen species (ROS) generation. Therefore, HNP-Cou-PD designed as a gene and PS co-delivery carrier might have promising applications in the future to precisely treat various types of cancers. STATEMENT OF SIGNIFICANCE: Multifunctional carriers incorporating genetic and photodynamic therapy (PDT) have drawn intense attention very recently, ascribing to their enhanced anticancer effects. However, in the present gene and PDT synergistic system, gene release strategies passively relying on tumor microenvironment often result in no or poor controllability compared with PDT (a spatial and temporal therapeutic modal), which may hinder their synergistic efficacy, especially in an on-demand manner. To resolve this problem, we designed a hollow silica nanoparticle-based dual-wavelength light-responsive gene and photosensitizer (PS) co-delivery platform to achieve photo-triggered gene and PDT synergistic therapy. We believe that our work may have extensive application prospects in precise treatment of various cancers and be of interest to the readership.
Subject(s)
Genetic Therapy , Nanoparticles , Neoplasms, Experimental , Photochemotherapy , Photosensitizing Agents , Plasmids , Silicon Dioxide , Animals , HeLa Cells , Hep G2 Cells , Humans , Interleukin-8/biosynthesis , Interleukin-8/genetics , Mice , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Neoplasms, Experimental/genetics , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Neoplasms, Experimental/therapy , Photosensitizing Agents/chemistry , Photosensitizing Agents/pharmacokinetics , Photosensitizing Agents/pharmacology , Plasmids/chemistry , Plasmids/genetics , Plasmids/pharmacokinetics , Plasmids/pharmacology , Silicon Dioxide/chemistry , Silicon Dioxide/pharmacology , Xenograft Model Antitumor AssaysABSTRACT
Gene therapy has become a promising approach for neurodegenerative disease treatment, however there is an urgent need to develop an efficient gene carrier to transport gene across the blood brain barrier (BBB). In this study, we strategically designed dual functionalized liposomes for efficient neuronal transfection by combining transferrin (Tf) receptor targeting and enhanced cell penetration utilizing penetratin (Pen). A triple cell co-culture model of BBB confirmed the ability of the liposomes to cross the barrier layer and transfect primary neuronal cells. In vivo quantification of PenTf-liposomes demonstrated expressive accumulation in the brain (12%), without any detectable cellular damage or morphological change. The efficacy of these nanoparticles containing plasmid ß-galactosidase in modulating transfection was assessed by ß-galactosidase expression in vivo. As a consequence of accumulation in the brain, PenTf-liposomes significantly induced gene expression in mice. Immunofluorescence studies of brain sections of mice after tail vein injection of liposomes encapsulating pDNA encoding GFP (pGFP) illustrate the superior ability of dual-functionalized liposomes to accumulate in the brain and transfect neurons. Taken together, the multifunctional liposomes provide an excellent gene delivery platform for neurodegenerative diseases.
Subject(s)
Blood-Brain Barrier/metabolism , Cell-Penetrating Peptides/metabolism , DNA/administration & dosage , Gene Transfer Techniques , Liposomes/metabolism , Neurons/metabolism , Transferrin/metabolism , Animals , Cells, Cultured , Coculture Techniques/methods , DNA/genetics , DNA/pharmacokinetics , Mice, Inbred C57BL , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/pharmacokinetics , Rats , Transfection/methods , beta-Galactosidase/geneticsABSTRACT
Decades of research into improving drug delivery to tumors has documented uptake of particulate delivery systems by resident macrophages in the lung, liver, and spleen, and correlated short circulation times with reduced tumor accumulation. An implicit assumption in these studies is that nanoparticles present in the blood are available for distribution to the tumor. This study documents significant levels of lipoplex uptake by circulating leukocytes, and its effect on distribution to the tumor and other organs. In agreement with previous studies, PEGylation dramatically extends circulation times and enhances tumor delivery. However, our studies suggest that this relationship is not straightforward, and that particle sequestration by leukocytes can significantly alter biodistribution, especially with non-PEGylated nanoparticle formulations. We conclude that leukocyte uptake should be considered in biodistribution studies, and that delivery to these circulating cells may present opportunities for treating viral infections and leukemia.
Subject(s)
Leukocytes/metabolism , Nanoparticles/metabolism , Polyethylene Glycols/metabolism , Animals , DNA/administration & dosage , DNA/pharmacokinetics , Female , Gene Transfer Techniques , Mice, Inbred BALB C , Mice, SCID , Neoplasms/metabolism , Plasmids/administration & dosage , Plasmids/pharmacokinetics , Tissue DistributionABSTRACT
Endothelial cells play a critical role in many physiological processes; therefore, there is increasing evidence that the future of many treatments for pathologies depends on the development of endothelium-targeting systems. Thus, we have incorporated the natural polysaccharide xanthan gum (XG) into sorbitan monooleate nanoparticles to provide them with a hydrophilic and negatively charged surface shell with stabilising properties and an inherent ability to target endothelial cells. Enhanced Green Fluorescent Protein plasmid (pEGFP) was incorporated into the nanosystem, and the protection ability and stability of this system was confirmed. Nanoparticle cytotoxicity and transfection capacity were successfully tested in Human Umbilical Vein Endothelial Cells (HUVECs) before confirming their biocompatibility in vivo. Finally, biodistribution studies after pEGFP-XG nanoparticle systemic administration to mice evidenced GFP expression in the vascular endothelium of lung, liver and kidney, thus confirming the potential of xanthan gum-functionalised span nanoparticles for gene targeting to endothelial cells.
Subject(s)
Drug Delivery Systems , Endothelial Cells/metabolism , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Plasmids/administration & dosage , Polysaccharides, Bacterial/administration & dosage , Polysaccharides, Bacterial/chemistry , Animals , Gene Targeting , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Mice , Particle Size , Plasmids/genetics , Plasmids/metabolism , Plasmids/pharmacokinetics , Polysaccharides, Bacterial/pharmacokinetics , Surface Properties , Tissue DistributionABSTRACT
The objective of the present study is to conjugate L-thyroxine PEI derivative onto another PEI to compensate the amine content of the whole structure which has been utilized for the ligand conjugation. Since αvß3 integrin receptors are over-expressed on cancer cells and there is binding site for L-thyroxine on these receptors, PEI conjugation by L-thyroxine along with restoring the PEI amine content might be an efficient strategy for targeted delivery using polymeric nanoparticles. The results demonstrated the ability of the PEI conjugate in the formation of nanoparticles with the size of around 210 nm with higher buffering capacity. The conjugated PEI derivative increased the transfection efficiency in the cell lines over-expressing integrin by up to two folds higher than unmodified PEI, whereas in the cell lines lacking the integrin receptors there was no ligand conjugation-associated difference in gene transfer ability. The specificity of transfection demonstrated the delivery of plasmid DNA through integrin receptors. Also, the results of in vivo imaging of the polyplexes revealed that 99mTc-labeled PEI/plasmid DNA complexes accumulated in kidney and bladder 4 h post injection. Therefore, this PEI derivative could be considered as an efficient targeted delivery system for plasmid DNA.
Subject(s)
Integrin alphaVbeta3/genetics , Nanoparticles/chemistry , Polyethyleneimine/chemistry , Transfection/methods , Animals , DNA/administration & dosage , DNA/chemistry , DNA/pharmacokinetics , Female , Genetic Vectors/administration & dosage , Genetic Vectors/chemistry , Genetic Vectors/pharmacokinetics , Hep G2 Cells , Humans , Mice , Mice, Inbred BALB C , Particle Size , Plasmids/administration & dosage , Plasmids/chemistry , Plasmids/pharmacokineticsABSTRACT
We studied the influence of the type and structure of polyethyleneimine on bioavailability and expression of plasmid DNA carrying IGF-1 gene. Polymers with different molecular weights (2.5, 10, 25, and 60 kDa) of linear and branching structure were studied. It was found that the time of polyplex circulation in the blood did not exceed 24 h and the maximum concentration of plasmid DNA was attained with complexes with a molecular weight of 60 kDa. Analysis of liver samples showed that administration of 60-kDa branched polyethyleneimine complex provides DNA protection from degradation for 4 h; in 24 h from the start of the experiment, its concentration was significantly higher than the concentration of other studied polyethyleneimines. The expression of plasmid IGF-1 DNA for this complex attained maximum in 4 h and was equal to 15.50 (7.98; 21.98) arb. units/ml. These results allow us to recommend using polyethyleneimines with branched structure and a molecular weight of 60 kDa for improving plasmid DNA protection and bioavailability.
Subject(s)
Drug Carriers/chemistry , Insulin-Like Growth Factor I/pharmacokinetics , Liver/chemistry , Plasmids/pharmacokinetics , Polyethyleneimine/chemistry , Animals , Animals, Outbred Strains , Biological Availability , Gene Expression , Injections, Intravenous , Insulin-Like Growth Factor I/genetics , Liver/metabolism , Male , Molecular Structure , Molecular Weight , Plasmids/blood , Rats , Structure-Activity Relationship , Transfection , TransgenesABSTRACT
Herein, five new α-tocopheryl cationic gemini lipids with hydroxyethyl bearing headgroups (THnS, n = 4, 5, 6, 8, 12) have been synthesized for efficient plasmid DNA (pDNA) delivery into cancer cells. Among these gemini lipid formulations, the lipid with an octamethylene [-(CH2)8] spacer (TH8S) showed the highest transfection efficiency (TE) that was comparable to that of the commercial standard lipofectamine 2000 (L2K) in terms of luciferase expression in HepG2 (liver hepatocellular carcinoma) cells. The addition of the helper lipid DOPE (1,2-dioleoyl phosphatidyl ethanolamine) with cationic lipids in mixed liposomes further enhanced the TE and the optimized molar ratio was 2 : 1 (DOPE : cationic lipid). The optimized co-liposomal formulation of TH8S (DOPE : TH8S = 2 : 1) showed a higher TE in HepG2, A549 (human lung carcinoma) and MCF7 (human breast adenocarcinoma) cells than other optimized co-liposomal formulations and was also significantly more potent than L2K. The comparison of the TE of DOPE-TH8S (2 : 1) with the gemini lipid T8T (the headgroup devoid of the hydroxyl group) further demonstrated the importance of the hydroxyethyl functionality at the level of the headgroup. Relatively good binding efficiency and easy release of pDNA (pGL3) were also observed with DOPE-TH8S (2 : 1) in the ethidium bromide (EB)-exclusion and re-intercalation assay, which may be the plausible reason for high TE. The lipoplexes were also characterized by atomic force microscopy (AFM), dynamic light scattering (DLS), zeta potential and small angle X-ray diffraction experiments. Greater cellular internalization of fluorescein tagged pDNA was also observed with DOPE-TH8S (2 : 1) lipoplexes compared to that with L2K. Retention of the TE of DOPE-TH8S (2 : 1) lipoplexes under high serum conditions was conferred by the presence of the tocopherol backbone and also the hydroxyethyl functionalities. The cellular internalization pathway of the lipoplexes was characterized by performing transfection experiment in the presence of inhibitors of different endocytic pathways and it was found to be caveolae mediated. An MTT based cell viability assay indicated that the lipoplex mediated gene delivery vectors exhibited low toxicity in all the three cancer cell lines studied.
Subject(s)
DNA/administration & dosage , Lipids/chemistry , Liposomes/chemistry , Plasmids/administration & dosage , Transfection/methods , Cations/chemical synthesis , Cations/chemistry , Cell Line, Tumor , DNA/pharmacokinetics , Ethanol/chemical synthesis , Ethanol/chemistry , Humans , Lipids/chemical synthesis , Liposomes/chemical synthesis , Phosphatidylethanolamines/chemical synthesis , Phosphatidylethanolamines/chemistry , Plasmids/pharmacokineticsABSTRACT
La resistencia a las polimixinas mediada por plásmidos (gen mcr-1) representa una amenaza para la salud pública, puesto que colistina es utilizada en la práctica médica como una de las últimas alternativas para el tratamiento de gérmenes multiresistentes. Este estudio describe la circulaciónde cepas de Enterobacterias que portan este gen de resistencia, aisladas de pacientes hospitalizados, así como también de la comunidad. Los hallazgos de la Red de Vigilancia de la Resistencia a los Antimicrobianos-Paraguay fueron de casi el 5 % (4,7) en cepas remitidas con criterio de sospecha, siendo las especies involucradas Escherichiacoli, Klebsiella pneumoniae y Salmonella Schwarzengrund. Además, por métodos moleculares se confirmaron en todas ellas la portación de otros genes de resistencia (KPC, CTX-M, Qnr B, Qnr S, aac (6`)-Ib-cr) asociados al mcr-1. Palabras claves: Enterobacterias, resistencia, colistina, mcr-1.
Resistance to polymyxins mediated by plasmids (mcr-1 gene) represents a threat to public health, since colistin is used in medical practice, as one of the last alternatives, for the treatment of multi-resistant germs. This study describes the circulation of strains of Enterobacteria that carry this resistance gene, isolated from hospitalized patients, as well as from the community. The findings of the Red de Vigilancia de la Resistencia a los AntimicrobianosParaguay were almost 5% (4.7) in strains submitted with suspicion criteria; the species involved being Escherichia coli, Klebsiella pneumoniae and Salmonella Schwarzengrund. In addition, molecular methods confirmed in all of them the carrying of other resistance genes (KPC, CTX-M, Qnr B, Qnr S, aac (6`)-Ib-cr) associated with mcr-1. Key words: Enterobacteria, resistance, colistin, mcr-1.